| 张丽华,吴东辰,王金华.PD-1/PD-L1抑制剂治疗晚期或复发性宫颈癌的研究进展[J].肿瘤学杂志,2022,28(3):185-190. |
| PD-1/PD-L1抑制剂治疗晚期或复发性宫颈癌的研究进展 |
| Progression of PD-1/PD-L1 Inhibitors in Advanced or Recurrent Patients with Cervical Cancer |
| 投稿时间：2022-01-10 |
| DOI：10.11735/j.issn.1671-170X.2022.03.B005 |
|
 |
| 中文关键词: 宫颈癌 PD-1/PD-L1 抑制剂 免疫治疗 |
| 英文关键词:cervical cancer PD-1/PD-L1 inhibitors immune therapy |
| 基金项目:江苏省医学重点人才（2016KJQWZDRC-02） |
|
| 摘要点击次数: 720 |
| 全文下载次数: 108 |
| 中文摘要: |
| 摘 要：近年来，免疫治疗成为肿瘤治疗的新热点，在2020年美国国立综合癌症网络（National Comprehensive Cancer Network，NCCN）指南中，Pembrolizumab被推荐可用于程序性死亡配体-1（programmed death-1 ligand 1，PD-L1）表达阳性或高微卫星不稳定性/错配修复缺陷的晚期宫颈癌的二线治疗。最近的几项研究也证明细胞程序性死亡受体-1及其配体(PD-1/PD-L1)抑制剂可提高晚期或复发性宫颈癌的生存率。全文总结近期关于PD-1/PD-L1抑制剂治疗晚期或复发性宫颈癌的作用机制、临床应用、免疫相关不良事件及耐药等相关研究进展。 |
| 英文摘要: |
| Abstract： In recent years， immunotherapy has become a new hotspot for tumor treatment， and in the 2020 NCCN(National Comprehensive Cancer Network) guidelines， pembrolizumab is recommended for second-line treatment for advanced cervical cancer with positive programmed death-1 ligand 1(PD-L1) expression or high microsatellite instability/different mismatch repair. Several recent studies have also demonstrated that PD-1/PD-L1 inhibitors improve survival rates for patients with advanced and recurrent cervical cancers. In this review， we summarize the recent research progress on the mechanism of action， clinical application， immune-related adverse events and drug resistance of PD-1/PD-L1 inhibitors in the treatment of advanced or recurrent cervical cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |